Congress is unlikely to codify the recent executive order to lower drug pricing as other US officials negotiate new prices, John Barkett, MBA, of Berkeley Research Group, explains.
John Barkett, MBA
Advertisement
Managing director in Berkeley Research Group's Healthcare Transactions and Strategy practice
Articles by John Barkett, MBA
The immediate impact of the recent executive order aimed at lowering drug prices is likely low, as it may take until 2027 before actions detailed in the order can be enacted.
The executive order that President Donald Trump signed to lower drug prices could come under legal challenges by the drug industry.
The executive order signed on May 12 has some differences from a previous executive order originally signed by the Trump administration in 2020.
The new executive order contains multiple provisions if pharmaceutical companies do not offer "most-favored nation" pricing on medication.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Survey Reveals Clinician Confidence Around Using AI in PA Process
3
How Medicaid Reforms Could Deepen State Coverage Gaps
4
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
5
